129 related articles for article (PubMed ID: 23831323)
1. Flagellin enhances tumor-specific CD8⁺ T cell immune responses through TLR5 stimulation in a therapeutic cancer vaccine model.
Nguyen CT; Hong SH; Sin JI; Vu HV; Jeong K; Cho KO; Uematsu S; Akira S; Lee SE; Rhee JH
Vaccine; 2013 Aug; 31(37):3879-87. PubMed ID: 23831323
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ.
Soong RS; Song L; Trieu J; Knoff J; He L; Tsai YC; Huh W; Chang YN; Cheng WF; Roden RB; Wu TC; Trimble CL; Hung CF
Clin Cancer Res; 2014 Nov; 20(21):5456-67. PubMed ID: 24893628
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity in mice and rhesus monkeys vaccinated with recombinant vaccinia virus expressing bivalent E7E6 fusion proteins from human papillomavirus types 16 and 18.
Zhao L; Liu B; Ren J; Feng J; Pang Z; Gao J; Zhang H; Tan W; Tian H; Ruan L
Virol J; 2011 Jun; 8():302. PubMed ID: 21672263
[TBL] [Abstract][Full Text] [Related]
4. A conserved E7-derived cytotoxic T lymphocyte epitope expressed on human papillomavirus 16-transformed HLA-A2+ epithelial cancers.
Riemer AB; Keskin DB; Zhang G; Handley M; Anderson KS; Brusic V; Reinhold B; Reinherz EL
J Biol Chem; 2010 Sep; 285(38):29608-22. PubMed ID: 20615877
[TBL] [Abstract][Full Text] [Related]
5. NSP4 as adjuvant for immunogenicity and design of effective therapeutic HPV16 E6/E7/L1 DNA vaccine in tumor-bearing and healthy C57BL/6 mice.
Sadr-Momtaz S; Aftabi M; Behboudi E; Naderi M; Hashemzadeh-Omran A; Moradi A
BMC Res Notes; 2023 Aug; 16(1):164. PubMed ID: 37550734
[TBL] [Abstract][Full Text] [Related]
6. Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity.
Tseng SH; Cheng MA; Farmer E; Ferrall L; Kung YJ; Lam B; Lim L; Wu TC; Hung CF
J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35459734
[TBL] [Abstract][Full Text] [Related]
7. Characterization of recombinant gorilla adenovirus HPV therapeutic vaccine PRGN-2009.
Pellom ST; Smalley Rumfield C; Morillon YM; Roller N; Poppe LK; Brough DE; Sabzevari H; Schlom J; Jochems C
JCI Insight; 2021 Apr; 6(7):. PubMed ID: 33651712
[TBL] [Abstract][Full Text] [Related]
8. CAF05: cationic liposomes that incorporate synthetic cord factor and poly(I:C) induce CTL immunity and reduce tumor burden in mice.
Hansen J; Lindenstrøm T; Lindberg-Levin J; Aagaard C; Andersen P; Agger EM
Cancer Immunol Immunother; 2012 Jun; 61(6):893-903. PubMed ID: 22095092
[TBL] [Abstract][Full Text] [Related]
9. Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors.
Dominiecki ME; Beatty GL; Pan ZK; Neeson P; Paterson Y
Cancer Immunol Immunother; 2005 May; 54(5):477-88. PubMed ID: 15750832
[TBL] [Abstract][Full Text] [Related]
10. Synthetic double-stranded RNA poly(I:C) as a potent peptide vaccine adjuvant: therapeutic activity against human cervical cancer in a rodent model.
Cui Z; Qiu F
Cancer Immunol Immunother; 2006 Oct; 55(10):1267-79. PubMed ID: 16362407
[TBL] [Abstract][Full Text] [Related]
11. Expression of a soluble IL-10 receptor enhances the therapeutic effects of a papillomavirus-associated antitumor vaccine in a murine model.
Silva JR; Sales NS; Silva MO; Aps LRMM; Moreno ACR; Rodrigues EG; Ferreira LCS; Diniz MO
Cancer Immunol Immunother; 2019 May; 68(5):753-763. PubMed ID: 30806747
[TBL] [Abstract][Full Text] [Related]
12. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid.
Chen W; Yan W; Huang L
Cancer Immunol Immunother; 2008 Apr; 57(4):517-30. PubMed ID: 17724588
[TBL] [Abstract][Full Text] [Related]
13. Tumor Microenvironment-Regulating Immunosenescence-Independent Nanostimulant Synergizing with Near-Infrared Light Irradiation for Antitumor Immunity.
Uthaman S; Pillarisetti S; Hwang HS; Mathew AP; Huh KM; Rhee JH; Park IK
ACS Appl Mater Interfaces; 2021 Feb; 13(4):4844-4852. PubMed ID: 33486952
[TBL] [Abstract][Full Text] [Related]
14. Flagellin-Stimulated Production of Interferon-β Promotes Anti-Flagellin IgG2c and IgA Responses.
Kang W; Park A; Huh JW; You G; Jung DJ; Song M; Lee HK; Kim YM
Mol Cells; 2020 Mar; 43(3):251-263. PubMed ID: 32131150
[TBL] [Abstract][Full Text] [Related]
15. Enhanced HPV16 E6/E7
Stegmann T; Wiekmeijer AS; Kwappenberg K; van Duikeren S; Bhoelan F; Bemelman D; Beenakker TJM; Krebber WJ; Arens R; Melief CJM
Cancer Immunol Immunother; 2023 Aug; 72(8):2851-2864. PubMed ID: 37222770
[TBL] [Abstract][Full Text] [Related]
16. IL-6 signaling in macrophages is required for immunotherapy-driven regression of tumors.
Beyranvand Nejad E; Labrie C; van Elsas MJ; Kleinovink JW; Mittrücker HW; Franken KLMC; Heink S; Korn T; Arens R; van Hall T; van der Burg SH
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33879600
[TBL] [Abstract][Full Text] [Related]
17. Genetic fusion of CCL11 to antigens enhances antigenicity in nucleic acid vaccines and eradicates tumor mass through optimizing T-cell response.
Qi H; Sun Z; Gao T; Yao Y; Wang Y; Li W; Wang X; Wang X; Liu D; Jiang JD
Mol Cancer; 2024 Mar; 23(1):46. PubMed ID: 38459592
[TBL] [Abstract][Full Text] [Related]
18. What is needed for effective antitumor immunotherapy? Lessons learned using Listeria monocytogenes as a live vector for HPV-associated tumors.
Hussain SF; Paterson Y
Cancer Immunol Immunother; 2005 Jun; 54(6):577-86. PubMed ID: 15650885
[TBL] [Abstract][Full Text] [Related]
19. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists.
Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT
ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282
[TBL] [Abstract][Full Text] [Related]
20. The TLR5 Agonist Flagellin Shapes Phenotypical and Functional Activation of Lung Mucosal Antigen Presenting Cells in Neonatal Mice.
Sharma P; Levy O; Dowling DJ
Front Immunol; 2020; 11():171. PubMed ID: 32132997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
